title: Clinical application of the different cross-reactivities of anti-insulin antibodies to insulin lispro to evaluate endogenous insulin secretion.
abstract: BACKGROUND
  Insulin analogs are often used to treat patients with diabetes. We evaluated the cross-reactivities of anti-insulin antibodies in two insulin immunoassay kits (Architect and ECLusys) against recombinant human insulin and insulin analogs, and measured insulin concentrations in the serum of the diabetic patients treated with only insulin lispro.
  
  
  METHODS
  Ten-fold dilutions of recombinant human insulins and insulin analogs were measured using Architect and ECLusys kits. The serum samples of 4 type 2 diabetic patients at fasting, and several time points after breakfast (25 kcal/kg) following subcutaneous injection of insulin lispro were measured by Architect, ECLusys and LISPro RIA kit.
  
  
  RESULTS
  The ECLusys kit could detect human insulin but not insulin analogs. The Architect kit detected human insulin and insulin analogs with similar recovery ratios. The difference in serum insulin concentrations measured by Architect and ECLusys assays reflected the concentration measured by LISPro insulin kit in the patients. The differences in the AUC between Architect and ECLusys assays were significantly correlated with the AUC for LISPro assay (p<0.01).
  
  
  CONCLUSIONS
  By exploiting the different cross-reactivities of anti-insulin antibodies to insulin analogs, it may be possible to measure the endogenous and exogenous insulin concentrations in diabetic patients treated with insulin analogs.
authors.affiliation: Department of Laboratory Medicine, Faculty of Medicine, Fukuoka University, Japan.
authors.forename: Ryoko
authors.initials: R
authors.lastname: Yoshida
authors.forename: Kumiko
authors.initials: K
authors.lastname: Ohkubo
authors.forename: Yuko
authors.initials: Y
authors.lastname: Akehi
authors.forename: Sadako
authors.initials: S
authors.lastname: Harada
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Shinohara
authors.forename: Hironobu
authors.initials: H
authors.lastname: Kawashima
authors.forename: Junko
authors.initials: J
authors.lastname: Ono
authors.forename: Akira
authors.initials: A
authors.lastname: Matsunaga
mesh_terms: D000368:Aged; D000918:Antibody Specificity; D019540:Area Under Curve; D001786:Blood Glucose / Q000032:analysis; D003429:Cross Reactions; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005215:Fasting; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000032:analysis*; D007118:Immunoassay; D007279:Injections, Subcutaneous; D007328:Insulin / Q000032:analysis* / Q000096:biosynthesis; D007330:Insulin Antibodies / Q000737:chemistry / Q000276:immunology*; D061268:Insulin Lispro / Q000008:administration & dosage / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000032:analysis; D012680:Sensitivity and Specificity
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D007330:Insulin Antibodies; D061268:Insulin Lispro; D011994:Recombinant Proteins